MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
REGN stock logo

REGN

Regeneron Pharmaceuticals, Inc.

$562.01
-1.89
 (-0.34%)
Exchange:  
Market Cap:   58.545B
Shares Outstanding:   15.364M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Leonard S. Schleifer
Full Time Employees:  15158
Address: 
777 Old Saw Mill River Road
Tarrytown
NY
10591-6707
US
Website:  https://www.regeneron.com
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

EPS

🔒 You are currently logged out

Login

It’s free

View full analyst estimates

Earnings Call

🔒 You are currently logged out

Login

It’s free

Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

(* All numbers are in thousands)

🔒 You are currently logged out

Login

It’s free

Balance Sheet

(* All numbers are in thousands)

🔒 You are currently logged out

Login

It’s free

Cash Flow Statement

(* All numbers are in thousands)

🔒 You are currently logged out

Login

It’s free

Analyst Estimates

(* All numbers are in thousands)

🔒 You are currently logged out

Login

It’s free

Current Key Metrics

🔒 You are currently logged out

Login

It’s free

Forward P/E Ratios

🔒 You are currently logged out

Login

It’s free

SWOT Analysis

🔒 You are currently logged out

Login

It’s free

At what price to buy it? –
Intrinsic Value Calculator


Calculate REGN Intrinsic Value

🔒 You are currently logged out

Login

It’s free

See in Nexus

Relevant news

29-09-2025 09:30
FDA Approves Label Extension of REGN’s Cholesterol Drug Evkeeza
24-09-2025 13:37
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bernstein Insights: Healthcare Leaders and Disruptors – 2nd Annual Healthcare Forum Transcript
19-09-2025 13:23
Regeneron says blood cancer therapy shows 100% response rate in precancerous disorder study
19-09-2025 13:15
Can Regeneron Change The Paradigm In Multiple Myeloma — And Undercut J&J?
17-09-2025 07:27
Regeneron’s bone disorder treatment succeeds in late-stage trial
09-09-2025 17:46
REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
MARKETSnap
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
    • Investment Compounding Calculator
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read